


# Eli Lilly and Co



Performance data quoted presents past performance; past performance does not guarantee future results; the investment return and principal value of an investment will fluctuate; an investor's shares, when redeemed, may be worth more or less than their original cost; current performance may be lower or higher than quoted performance data.

Inc. Statement	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
Revenue	19.62B	19.96B	21.22B	19.97B	21.49B	22.32B	24.54B	28.32B	28.54B	34.12B	40.86B
Operating Margin	16.97%	18.00%	18.24%	21.28%	28.04%	26.88%	28.94%	28.01%	30.32%	31.61%	37.02%
EBIT Margin	16.05%	14.79%	16.77%	12.67%	18.25%	25.39%	30.93%	22.94%	25.01%	20.63%	26.54%
Effective Tax Rate	20.32%	13.68%	18.86%	103.7%	14.39%	11.93%	14.33%	9.32%	8.25%	20.05%	17.54%
Net Income	2.390B	2.408B	2.738B	-204.10M	3.232B	8.318B	6.194B	5.582B	6.245B	5.240B	8.370B
EPS Basic	2.23	2.27	2.59	-0.19	3.14	8.93	6.82	6.15	6.93	5.82	9.295
EPS Diluted	2.23	2.26	2.58	-0.19	3.13	8.89	6.79	6.12	6.90	5.80	9.25

Balance Sheet	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Last Qtr.
Total Assets	36.31B	35.57B	38.81B	44.98B	43.91B	39.29B	46.63B	48.81B	49.49B	64.01B	75.61B
Total Liabilities	20.92B	20.98B	24.73B	33.31B	33.00B	36.59B	40.81B	39.65B	38.71B	53.14B	61.29B
Financial Debt	8.552B	8.518B	10.85B	14.24B	10.95B	15.99B	17.37B	17.77B	17.26B	26.39B	31.12B
Shareholders Equity	15.37B	14.57B	14.01B	11.59B	9.829B	2.607B	5.642B	8.979B	10.65B	10.77B	14.24B

Cash Flow	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
Cash from Operations	4.458B	2.965B	4.851B	5.616B	5.524B	4.837B	6.500B	7.366B	7.586B	4.240B	6.032B
Cash from Investing	-3.909B	26.80M	-3.139B	-3.784B	1.906B	-8.083B	-2.259B	-2.868B	-3.763B	-7.153B	-10.31B
Cash from Financing	-166.40M	-3.111B	-559.80M	142.60M	-5.905B	-2.324B	-3.137B	-4.131B	-5.407B	3.496B	5.000B
Free Cash Flow	2.892B	1.338B	3.759B	3.452B	2.506B	3.483B	4.470B	5.388B	4.600B	-3.152B	-2.275B

Dividend	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
Dividend Per Share	1.96	2.00	2.04	2.08	2.25	2.58	2.96	3.40	3.92	4.52	5.03
Payout Ratio	87.90%	88.33%	78.85%	-1.07K%	71.53%	28.97%	43.38%	55.30%	56.62%	77.65%	--

Profitability	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
Return on Assets	6.68%	6.70%	7.36%	-0.49%	7.27%	20.00%	14.42%	11.70%	12.71%	9.23%	--
Return on Equity	14.48%	16.07%	19.10%	-1.59%	28.63%	122.3%	145.3%	74.52%	62.67%	48.43%	--
Return on Invested Capital	10.33%	10.48%	11.66%	-0.82%	13.89%	42.41%	30.63%	23.04%	23.54%	16.61%	--

Estimates	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	2024	2025	2026
EPS	4.793	5.660	6.311	7.147	6.84	22.69	29.24	29.58
Revenue	12.86B	14.31B	15.23B	16.76B	16.61B	58.91B	70.43B	70.29B

Shareholder Friendliness	Liquidity	Short Interest
Dividend Yield	Quick Ratio Annual	Short Interest
Net Payout Yield	Current Ratio Ann	Days to Cover Short
Net Buyback Yield	Working Capital Ann	Percent of Float Short
Debt Paydwn Yield	EBIT/Int Expense Ann	% of Shr Outst Short

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Currency: USD

Symbol: LLY Price - Feb. 5, 2025 842.18  
 Sector: Health Care Price Target 975.09  
 Industry: Pharmaceuticals 52 Week High - Aug. 22, 2024 972.53  
 Consensus Rating: Outperform 52 Week Low - Feb. 6, 2024 707.02  
 Y-Rating: Neutral Market Cap 799.49B  
 Last Fiscal Period: --

Performance	1M	3M	YTD	1Y*	3Y*	5Y*	10Y*
Total Return	7.70%	4.66%	9.09%	20.03%	52.99%	43.56%	30.45%
Price Return	7.70%	4.48%	9.09%	19.26%	51.48%	41.71%	27.99%

\*Figures are annualized.

Comparables	Total Returns			Valuation (TTM)	
	1Y*	3Y*	5Y*	P/E	P/S
LLY	20.03%	52.99%	43.56%	91.05	18.64
AMGN	-1.50%	15.08%	9.11%	40.77	4.975
BIIB	-39.82%	-13.07%	-15.25%	13.15	2.211
VRTX	13.88%	26.38%	15.20%	--	11.96

\*Figures are annualized.

Growth	3Y	5Y	10Y
	Revenue	11.62%	9.69%
Operating Income	14.95%	12.35%	6.88%
EPS Basic	-5.15%	13.14%	3.00%
Total Dividends Paid	14.84%	11.97%	6.73%
Book Value	24.06%	1.85%	-4.81%
Total Assets	11.13%	7.83%	6.15%

Valuation	TTM	3Y Med.	5Y Med.	Ind. Avg.
PE Ratio	91.05	74.03	48.71	28.06
PS Ratio	18.64	14.96	9.844	4.436
PB Ratio	56.14	39.88	35.80	5.890
Price/FCF	--	--	--	24.41
EV/EBITDA	66.10	55.86	37.36	16.93
EV/EBIT	76.28	67.13	45.89	23.61
EV/Revenue	20.24	16.27	10.76	4.976
EV/FCF	-363.55	49.67	44.40	20.04
EV/Assets	10.91	8.532	8.532	2.251
P/E Forward	37.12	--	--	--
P/S Forward	13.57	--	--	--
PEG Forward	0.1275	--	--	--

Risk	3Y	5Y	10Y
Beta	0.3454	0.4163	0.3618
Standard Deviation	29.63%	31.04%	26.66%
Historical Sharpe Ratio	1.564	1.338	1.054
Max Drawdown	24.27%	24.27%	24.27%
VaR 5%	2.70%	2.55%	2.43%
Historical Sortino	3.406	2.884	2.160

2025 YCharts, Inc. All Rights Reserved. YCharts, Inc. (YCharts) is not registered with the U.S. Securities and Exchange Commission (or with the securities regulatory authority or body of any state or any other jurisdiction) as an investment adviser, broker-dealer or in any other capacity, and does not purport to provide investment advice or make investment recommendations. This report has been generated using data manually input by the creator of this report combined with data and calculations from YCharts.com and is intended solely to assist you or your investment or other adviser(s) in conducting investment research. You should not construe this report as an offer to buy or sell, as a solicitation of an offer to buy or sell, or as a recommendation to buy, sell, hold or trade, any security or other financial instrument. For further information regarding your use of this report, please go to: <https://get.ycharts.com/disclosure/>